medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2022, Number 1

<< Back Next >>

Rev Mex Urol 2022; 82 (1)

Abdominal aorta calcifications in patients with kidney stones, is there a link?

Basulto-Martínez M, Cueto VGJ, Arenas-Aquino AE, Espinosa AJE, Meza-Bosquez DM, Ortegón-Gallareta R, Esqueda-Mendoza A, Flores TJP

Language: English
References: 23
Page:
PDF size: 253.96 Kb.


ABSTRACT

Objective: To investigate the correlations between abdominal aortic calcifications (AAC) and the underlying urinary metabolic abnormalities in stone-formers (SF).
Methods: Patients with a 24 h urinary panel and computed tomography scan were included. The Kauppila Score (KS) was used to quantitatively assess AAC; clinical data and stone information were also recorded. The Spearman correlation was utilized.
Results: A total of 54 patients were included, the mean age was 46.4±11.2, 75.9% were female, and 59.3% had AAC. Hypertension and AAC were associated (p=0.026), and the KS was higher in patients with hypertension. Hypocitraturia (98.1%) and hypercalciuria (16.7%) were the most frequent urinary abnormalities, but they were unrelated to AAC (p›0.05). The 24 urinary panel, blood biochemistry, stone burden and hardness, and body mass index were not correlated to the KS (p›0.05). Limitations: This work had the following limitations: its retrospective nature, a relatively small sample, and the lack of an automated informatics-based assessment of AAC.
Conclusion: The link between cardiovascular diseases and kidney stones is still to be elucidated. Our finding differs from the other few studies reported on the literature, as no correlation was found between AAC and the urinary metabolic abnormalities in SF.


REFERENCES

  1. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2– 3):e86-96.

  2. Yasui T, Okada A, Hamamoto S, Ando R, Taguchi K, Tozawa K, et al. Pathophysiologybased treatment of urolithiasis. International Journal of Urology. 2017;24(1):32–8. doi: 10.1111/iju.13187

  3. Basulto-Martínez M, Olvera-Posada D, Velueta-Martínez IA, Méndez-Probst C, Flores-Tapia JP, Penniston K, et al. Quality of life in patients with kidney stones: translation and validation of the Spanish Wisconsin Stone Quality of Life Questionnaire. Urolithiasis. 2020;48(5):419–24. doi: 10.1007/s00240-020- 01192-9

  4. Smith AK. Campbell-Walsh Urology. In: Wein A, ed. Campbell-Walsh Urology. 11th ed. Philadelphia: Elsevier; 2016:1170-1299

  5. Alelign T, Petros B. Kidney Stone Disease: An Update on Current Concepts. Adv Urol. 2018;2018:3068365. doi: 10.1155/2018/3068365

  6. Ratkalkar VN, Kleinman JG. Mechanisms of Stone Formation. Clin Rev Bone Miner Metab. 2011;9(3–4):187–97. doi: 10.1007/s12018- 011-9104-8

  7. Taylor EN, Stampfer MJ, Curhan GC. Obesity, Weight Gain, and the Risk of Kidney Stones. JAMA. 2005;293(4):455–62. doi: 10.1001/ jama.293.4.455

  8. Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68(3):1230–5. doi: 10.1111/j.1523- 1755.2005.00516.x

  9. Shamah-Levy T, Campos-Nonato I, Cuevas- Nasu L, Hernández-Barrera L, Morales-Ruán M del C, Rivera-Dommarco J, et al. Sobrepeso y obesidad en población mexicana en condición de vulnerabilidad. Resultados de la Ensanut 100k. Salud Pública de México. 2019;61(6, novdic): 852–65. doi: 10.21149/10585

  10. Rojas-Martínez R, Basto-Abreu A, Aguilar- Salinas CA, Zárate-Rojas E, Villalpando S, Barrientos-Gutiérrez T. Prevalencia de diabetes por diagnóstico médico previo en México. Salud Pública de México. 2018;60(3, may-jun):224–32. doi: 10.21149/8566

  11. Campos-Nonato I, Hernández-Barrera L, Pedroza-Tobías A, Medina C, Barquera S. Hipertensión arterial en adultos mexicanos: prevalencia, diagnóstico y tipo de tratamiento. Ensanut MC 2016. Salud Pública de México. 2018;60(3, may-jun):233–43. doi: 10.21149/8813

  12. Cupisti A, D’Alessandro C, Samoni S, Meola M, Egidi MF. Nephrolithiasis and hypertension: possible links and clinical implications. J Nephrol. 2014;27(5):477–82. doi: 10.1007/ s40620-014-0068-x

  13. Shang W, Li Y, Ren Y, Yang Y, Li H, Dong J. Nephrolithiasis and risk of hypertension: a meta-analysis of observational studies. BMC Nephrology. 2017;18(1):344. doi: 10.1186/ s12882-017-0762-8

  14. Saeed R. Khan. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol Res. 2012 Apr;40(2):95–112. doi: 10.1007/s00240-011-0448-9

  15. An C, Lee H-J, Lee HS, Ahn SS, Choi BW, Kim M-J, et al. CT-based abdominal aortic calcification score as a surrogate marker for predicting the presence of asymptomatic coronary artery disease. Eur Radiol. 2014;24(10):2491–8. doi: 10.1007/s00330-014- 3298-3

  16. Patel ND, Ward RD, Calle J, Remer EM, Monga M. Vascular Disease and Kidney Stones: Abdominal Aortic Calcifications Are Associated with Low Urine pH and Hypocitraturia. Journal of Endourology. 2017;31(9):956–61. doi: 10.1089/end.2017.0350

  17. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PWF. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year followup study. Atherosclerosis. 1997;132(2):245–50. doi: 10.1016/S0021-9150(97)00106-8

  18. Tibblin G. A Population Study of 50-yearold Men. Acta Medica Scandinavica. 1965;178(4):453–9. doi: 10.1111/j.0954- 6820.1965.tb04290.x

  19. Borghi L, Meschi T, Guerra A, Briganti A, Schianchi T, Allegri F, et al. Essential arterial hypertension and stone disease. Kidney Int. 1999;55(6):2397–406. doi: 10.1046/j.1523- 1755.1999.00483.x

  20. Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. J Nephrol. 2011;24(1):23–34. doi: 10.5301/jn.2010.4729

  21. Coe FL, Evan AP, Worcester EM, Lingeman JE. Three pathways for human kidney stone formation. Urol Res. 2010;38(3):147–60. doi: 10.1007/s00240-010-0271-8

  22. Kim Y-J, Park MS, Kim W-T, Yun S-J, Kim W-J, Lee S-C. Hypertension influences recurrent stone formation in nonobese stone formers. Urology. 2011;77(5):1059–63. doi: 10.1016/j. urology.2010.07.492

  23. Shavit L, Girfoglio D, Vijay V, Goldsmith D, Ferraro PM, Moochhala SH, et al. Vascular Calcification and Bone Mineral Density in Recurrent Kidney Stone Formers. CJASN. 2015;10(2):278–85. doi: 10.2215/ CJN.06030614




2020     |     www.medigraphic.com